A MedTech targeting early detection of esophageal cancer has raised 拢32.5m in Series B funding.
Founded by experts at the University of Cambridge, Cyted Health is pioneering the development of minimally invasive cell collection coupled with proprietary biomarker discovery to transform the detection of pre-cancerous, cancerous and inflammatory esophageal conditions.
The round was led by the British 老九品茶 Bank – which contributed 拢5m – EQT Life Sciences and Advent Life Sciences, with continued support from existing investors Morningside and BGF.
Cyted鈥檚 technology has already demonstrated significant success across the NHS, completing over 35,000 tests and building a robust portfolio of peer-reviewed publications.
The financing will be used to accelerate the commercial expansion of Cyted鈥檚 diagnostics platform in the US, consolidate existing commercial success across the UK, and expand its portfolio of advanced diagnostic tests.聽
鈥淐yted is an excellent example of the kind of high-impact business we aim to back. Their innovation has the potential to transform early cancer detection and create lasting health outcomes both in the UK and globally,鈥� said Carmine Circelli, director, life sciences at British 老九品茶 Bank.
Ex-Aston Martin CEO’s startup buys Oxford spinout after 拢5m raise
Marcel Gehrung, CEO and co-founder of Cyted Health, said: 鈥淭his Series B financing marks a defining moment for Cyted as we continue to deepen our commitment to detecting esophageal diseases earlier.聽
鈥淭his investment will help us consolidate our leading position in the market by expanding our US presence and adding new life-saving innovations to our advanced diagnostics portfolio.鈥�
Executive shake-up at Ultimate Products as founder takes new role